The shares of Acorda Therapeutics Inc. (NASDAQ:ACOR) has been pegged with a rating of Neutral by H.C. Wainwright in its latest research note that was published on August 14, 2019. The Healthcare company has also assigned a $6 price target. H.C. Wainwright wasn’t the only research firm that published a report of Acorda Therapeutics Inc., with other equities research analysts also giving their opinion on the stock. The stock had earned Sell rating from Goldman Markets when it published its report on December 11, 2018. The stock was given Hold rating by Stifel in its report released on August 07, 2018, the day when the price target on the stock was placed at 25. Piper Jaffray was of a view that ACOR is Overweight in its latest report on February 16, 2018. H.C. Wainwright thinks that ACOR is worth Buy rating. This was contained in the firm’s report on January 17, 2018 in which the stock’s price target was also moved to 31.
Amongst the analysts that rated the stock, 2 have recommended investors to sell it, 4 believe it has the potential for further growth, thus rating it as Hold while 1 advised investors to purchase the stock. The consensus currently stands at a Hold while its average price target is $3.75. The price of the stock the last time has raised by 34.90% from its 52-Week high price while it is -87.47% than its 52-Week low price. A look at the stock’s other technical shows that its 14-day RSI now stands at 47.03.
The shares of the company added by 1.52% during the trading session on Wednesday, reaching a low of $1.985 while ending the day at $2.01. During the trading session, a total of 1.76 million shares were traded which represents a 29.15% incline from the average session volume which is 2.49 million shares. ACOR had ended its last session trading at $1.98. Acorda Therapeutics Inc. debt-to-equity ratio currently stands at 1.25, while its quick ratio hovers at 3.10 ACOR 52-week low price stands at $1.49 while its 52-week high price is $16.04.
The company in its last quarterly report recorded -$0.52 earnings per share which is above the predicted by most analysts. The Acorda Therapeutics Inc. generated 119.91 million in revenue during the last quarter. In the second quarter last year, the firm recorded -$0.65 earnings per share. Compared to the same quarter last year, the firm’s revenue was up by 178.85%. Acorda Therapeutics Inc. has the potential to record -3.00 EPS for the current fiscal year, according to equities analysts.
Investment analysts at Stephens published a research note on January 27, 2020 where it informed investors and clients that American Express Company (NYSE:AXP) is now rated as Equal-Weight. Their price target on the stock stands at $144. Robert W. Baird also rated AXP as Initiated on January 09, 2020, with its price target of $124 suggesting that AXP could surge by 5.0% from its current share price. Even though the stock has been trading at $132.63/share, analysts expect it to surge by 0.46% to reach $140.26/share. It started the day trading at $133.72 and traded between $132.53 and $133.24 throughout the trading session.
A look at its technical shows that AXP’s 50-day SMA is 126.92 while its 200-day SMA stands at 122.13. The stock has a high of $138.13 for the year while the low is $106.24. The stock, however, witnessed a rise in its short on 01/31/20. Compared to previous close which recorded 7.77 M shorted shares, the short percentage went lower by -1.63%, as 7.64M ACOR shares were shorted. At the moment, only 0.96% of American Express Company shares were sold short. The company’s P/E ratio currently sits at 16.68, while the P/B ratio is 4.77. The company’s average trading volume currently stands at 2.97M shares, which means that the short-interest ratio is just 2.62 days. Over the past seven days, the company moved, with its shift of -0.27%. Looking further, the stock has raised 10.21% over the past 90 days while it gained 5.48% over the last six months.
This move now sees The Berkshire Hathaway, Inc. (Investm. selling 0 shares in the last quarter, thus it now holds 151,610,700 shares of AXP, with a total valuation of $19,689,681,609. The Vanguard Group, Inc. meanwhile sold more AXP shares in the recently filed quarter, changing its stake to $6,326,035,492 worth of shares.
Similarly, SSgA Funds Management, Inc. decreased its American Express Company shares by 2.10% during the recently filed quarter. After selling 34,846,177 shares in the last quarter, the firm now controls -747,276 shares of American Express Company which are valued at $4,525,473,007. In the same vein, BlackRock Fund Advisors decreased its American Express Company shares by during the most recent reported quarter. The firm bought 794,878 shares during the quarter which decreased its stakes to 30,415,514 shares and is now valued at $3,950,062,803. Following these latest developments, around 0.10% of American Express Company stocks are owned by institutional investors and hedge funds.